The failure rate for current plastic dialysis
grafts is high, with complications
that include infection, thrombosis
and neo-intimal hyperplasia.
Investigational HAVs are found to be
more resistant to these failure modes
in initial investigational trials.
Using investigational HAVs means
that other surrogate blood vessels,
e.g., saphenous vein from the leg,
won’t have to be removed from the
patient. This approach saves the
patient’s own vein and the
patient from additional operations.
Investigational HAVs have the
potential to be grown, stored and
immediately available for vascular
access or as a peripheral graft
throughout the body.
Surgical creation of vascular
accesses may be costly and
complications often arise. The more
durable investigational HAVs have
the potential to avoid complications
and more surgeries, yielding
potential significant health care
More than 465,000 people in the
U.S. with End-Stage Renal Disease
(ESRD) undergo hemodialysis
Current vascular access options
have poor durability, or functional
patency, and ultimately fail.
investigational HAVs) could serve as
a potential alternative to synthetic
fluoropolymers (plastic grafts)
in these patients.
In clinical trials, HUMACYL® has
shown the potential to resist
inflammatory and immune
responses from the recipient. These
attributes make HUMACYL® a great
alternative and confer potential
remarkable advantages vs. other
potentially competing and largely